A new myeloma: three tests, sent together
The clue is on the routine panel
An invented example. This patient returns in the next two tabs.
First-day orders
In 467 patients with myeloma, electrophoresis plus free light chains found every case the full five-test panel found. Six were found only because free light chains had been added.Mayo Clinic (Katzmann 2009). In another series of 1,027 patients, 20% made light chains only and 3% made no measurable protein.
Blood count, calcium, creatinine, albumin.
Beta-2 microglobulin and lactate dehydrogenase (LDH), for staging.
Whole-body low-dose CT in place of the X-ray skeletal survey. PET/CT or MRI are alternatives.
Four emergencies at presentation
Spinal cord compression
New back pain with weakness, numbness or bladder change. MRI of the whole spine the same day, and dexamethasone.
Thick blood (hyperviscosity)
Blurred vision, nosebleeds, confusion. Plasma exchange on symptoms, without waiting for a viscosity result, and before any red cell transfusion.
Severe high calcium
Fluids first. Calcitonin for speed, then zoledronic acid to hold it, or denosumab when the kidney is failing.
Kidney failure
Treatment starts the same day. See the next tab.
Organ damage: C, R, A, B
Calcium
Above 11 mg/dL, or more than 1 mg/dL above the laboratory limit.
Renal
Creatinine above 2 mg/dL, or clearance under 40 mL/min.
Anemia
Hemoglobin under 10 g/dL, or more than 2 g/dL below normal.
Bone
One or more holes in bone (lytic lesions): 5 mm or larger on CT or PET/CT, any size on X-ray.
The damage has to come from the plasma cells. Kidney failure from diabetes does not count.
Is it myeloma, or a step before it?
Myeloma needs 10% plasma cells or a biopsy-proven plasmacytoma, plus organ damage or a marker. Organ damage with a small clone: look for amyloidosis, kidney deposits or a plasmacytoma, and repeat the marrow or imaging. A single plasmacytoma without organ damage is a solitary plasmacytoma, not smoldering myeloma.
Sources
Retrieved from PubMed (abstracts and full text) and the criteria pages of the International Myeloma Working Group, read on Oct 15, 2026.
- Rajkumar SV, et al. Updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014. doi:10.1016/S1470-2045(14)70442-5
- Katzmann JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009. doi:10.1373/clinchem.2009.126664
- Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003. doi:10.4065/78.1.21
- van Hoeven KH, et al. The anion gap and routine serum protein measurements in monoclonal gammopathies. Clin J Am Soc Nephrol 2011. doi:10.2215/CJN.07380711
- Hillengass J, et al. Imaging in monoclonal plasma cell disorders. Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30309-2
- Gertz MA. Acute hyperviscosity. Blood 2018. doi:10.1182/blood-2018-06-846816
- El-Hajj Fuleihan G, et al. Treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2023. doi:10.1210/clinem/dgac621
- Dimopoulos MA, et al. Daratumumab or active monitoring for high-risk smoldering myeloma. N Engl J Med 2025. doi:10.1056/NEJMoa2409029
Myeloma kidney: the first 48 hours
The invented patient from the first tab: creatinine 5.8 mg/dL, calcium 13.1 mg/dL, and the free light chains come back very high.
What blocks the kidney
Day zero
Tonight
Same day as the diagnosis
The mistake
When light chains fell 60% by day 21, 80% of kidneys recovered.39 patients with biopsy-proven cast injury (Hutchison 2011). No threshold: every further drop helped. Median survival was 43 months with kidney recovery and 8 months without.
Fluids aim for a good urine output, unless the patient is already overloaded.
What to add, and what did not help
Daratumumab also needs no kidney dose change and lowers light chains quickly, but the kidney-rescue data are one small phase 2 trial and case series, not a randomized trial.
Does the kidney need a biopsy?
The medication list, with a failing kidney
Dexamethasone.
Daratumumab.
Zoledronic acid: lower dose, or none.
Anti-inflammatory painkillers: stop.
IV contrast: avoid.
The doses are in "The numbers", below.
Calcium: watch for the overshoot
Low calcium after treatment is more likely with kidney failure and low vitamin D. If calcium is then replaced, recheck it every day and cut back as it normalizes: the bone disease is still there.
Check yourself: myelomaCreatinine 5.8, calcium 13.1, hemoglobin 8.4, total protein 5.6. The electrophoresis shows no spike. Is myeloma ruled out, and what happens tonight?
No. A myeloma that makes only light chains often shows no spike: the serum free light chains and the immunofixation find it. Tonight: fluids, stop anti-inflammatory painkillers and contrast, call the myeloma attending. If the light chains are very high, dexamethasone and bortezomib start the same day, without waiting for the marrow result.
The numbers
| Drug | Clearance 30 to 60 mL/min | Under 30 mL/min | On dialysis |
|---|---|---|---|
| Lenalidomide | 10 mg daily | 15 mg every other day | 5 mg daily, after the session |
| Zoledronic acid | Reduced dose | Not recommended | Not recommended |
- Kidney impairment at diagnosis: creatinine 2 mg/dL or higher in 19% of 1,027 patients.
- MYRE, patients not on dialysis: kidney response at 3 months in 41 of 92 with bortezomib and dexamethasone, and 47 of 92 with cyclophosphamide added. Not a significant difference.
- MYRE, patients on dialysis: off dialysis at 3 months 41% with a high-cutoff filter against 33% (the main endpoint, not significant); at 12 months 61% against 38%.
- EuLITE: off dialysis at 90 days 56% against 51%; lung infections 14 against 3 with the high-cutoff filter. Every patient in both filter trials received bortezomib-based treatment.
- Denosumab against zoledronic acid in myeloma bone disease: kidney toxicity 10% against 17%, low calcium 17% against 12%.
Sources
Retrieved from PubMed (abstracts) and current FDA labels, read on Oct 15, 2026.
- Hutchison CA, et al. Early reduction of serum free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011. doi:10.1681/ASN.2010080857
- Dimopoulos MA, et al. IMWG recommendations for myeloma-related renal impairment. J Clin Oncol 2016. doi:10.1200/JCO.2015.65.0044
- Dimopoulos MA, et al. Management of multiple myeloma-related renal impairment: IMWG. Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00223-1
- Bridoux F, et al. Bortezomib-dexamethasone with or without cyclophosphamide in cast nephropathy (MYRE). J Clin Oncol 2020. doi:10.1200/JCO.20.00298
- Bridoux F, et al. High-cutoff versus conventional hemodialysis in myeloma cast nephropathy (MYRE). JAMA 2017. doi:10.1001/jama.2017.17924
- Hutchison CA, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy (EuLITE). Lancet Haematol 2019. doi:10.1016/S2352-3026(19)30014-6
- Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003. doi:10.4065/78.1.21
- Raje N, et al. Denosumab versus zoledronic acid in bone disease of newly diagnosed myeloma. Lancet Oncol 2018. doi:10.1016/S1470-2045(18)30072-X
- FDA labels: bortezomib, lenalidomide, zoledronic acid, daratumumab and hyaluronidase, denosumab.
First treatment in 2026: four drugs
The same invented patient, a week later: the marrow confirms myeloma and the creatinine is falling on bortezomib and dexamethasone. What comes next?
Choosing the first regimen
VRd = bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone.
With a failing kidney, start bortezomib and dexamethasone the same day. Daratumumab needs no dose change (see the kidney tab), though the quadruplet trials excluded severe kidney failure; lenalidomide is added later at a kidney-adjusted dose.
What the antibody added
- CEPHEUS (no transplant, daratumumab added to VRd): no detectable disease in 61% against 39%. That means no myeloma found among 100,000 marrow cells.
- MAIA (not for transplant, daratumumab added to lenalidomide and dexamethasone): median survival 90 months against 64.
One test that cannot wait
Send FISH on the first marrow: the sample cannot be repeated once treatment has cleared it.FISH is chromosome testing on the plasma cells. It decides who is high risk. The 2025 definition is in the fold below.
Before the first dose of daratumumab or isatuximab
CD38, the antibody's target, is also on red cells, so the blood bank cannot clear units the usual way. It also shows on electrophoresis as a small extra band, which can be mistaken for leftover myeloma. Daratumumab has reactivated hepatitis B.
Prophylaxis from cycle 1
Check yourself: first treatmentThe same patient, now 71, creatinine 1.6 and falling, marrow 40% plasma cells. What is the regimen, and what two things must be done before the first antibody dose?
Daratumumab plus VRd: the CEPHEUS population, under 80 and not frail. Before the first antibody dose: a type and screen with the blood bank told, and hepatitis B serology. FISH was already sent on the diagnostic marrow.
Who is high risk: the 2025 definition
Any one of the four.
Staging in one minute
- International Staging System: stage I is beta-2 microglobulin under 3.5 mg/L with albumin 3.5 g/dL or higher. Stage III is beta-2 microglobulin 5.5 or higher. Stage II is everything else.
- The revised system adds lactate dehydrogenase (LDH) and FISH. Stage I needs normal LDH and none of del(17p), t(4;14), t(14;16). Revised stage III is ISS stage III plus a high LDH or one of those changes. Five-year survival was 82%, 62% and 40%.
One drug that is not standard
- Venetoclax. It works in myeloma carrying t(11;14), but the first randomized trial in unselected patients had more deaths with it, mostly infections, and the trial restricted to t(11;14) missed its main endpoint (9.9 against 5.8 months without progression, not a significant difference). It has no myeloma approval.
Sources
Retrieved from PubMed (abstracts), FDA labels and the manufacturer's approval announcements, read on Oct 15, 2026. In the United States, daratumumab with VRd is labeled for transplant-eligible patients and, from CEPHEUS, for transplant-ineligible patients only (not for a transplant deferred by choice). It is also labeled with lenalidomide and dexamethasone. Isatuximab is labeled with VRd for transplant-ineligible patients.
- Sonneveld P, et al. Daratumumab, bortezomib, lenalidomide and dexamethasone for multiple myeloma (PERSEUS). N Engl J Med 2024. doi:10.1056/NEJMoa2312054
- Facon T, et al. Isatuximab, bortezomib, lenalidomide and dexamethasone for multiple myeloma (IMROZ). N Engl J Med 2024. doi:10.1056/NEJMoa2400712
- Usmani SZ, et al. Daratumumab plus VRd in transplant-ineligible or deferred myeloma (CEPHEUS). Nat Med 2025. doi:10.1038/s41591-024-03485-7
- Facon T, et al. Daratumumab, lenalidomide and dexamethasone (MAIA), final survival. Leukemia 2026. doi:10.1038/s41375-026-03097-9
- Avet-Loiseau H, et al. Consensus definition of high-risk multiple myeloma. J Clin Oncol 2025. doi:10.1200/JCO-24-01893
- Greipp PR, et al. International staging system for multiple myeloma. J Clin Oncol 2005. doi:10.1200/JCO.2005.04.242
- Palumbo A, et al. Revised International Staging System. J Clin Oncol 2015. doi:10.1200/JCO.2015.61.2267
- Chapuy CI, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015. doi:10.1111/trf.13069
- McCudden C, et al. Monitoring myeloma patients treated with daratumumab: the interference. Clin Chem Lab Med 2016. doi:10.1515/cclm-2015-1031
- Terpos E, et al. Treatment of multiple myeloma-related bone disease. Lancet Oncol 2021. doi:10.1016/S1470-2045(20)30559-3
- Drayson MT, et al. Levofloxacin prophylaxis in newly diagnosed myeloma (TEAMM). Lancet Oncol 2019. doi:10.1016/S1470-2045(19)30506-6
- Sanfilippo KM, et al. A clot risk score for myeloma on lenalidomide-type drugs (IMPEDE VTE). Am J Hematol 2019. doi:10.1002/ajh.25603
- Li A, et al. A second clot risk score (SAVED). J Natl Compr Canc Netw 2019. doi:10.6004/jnccn.2018.7273
- Kumar SK, et al. Venetoclax or placebo with bortezomib and dexamethasone (BELLINI). Lancet Oncol 2020. doi:10.1016/S1470-2045(20)30525-8
- Popat R, et al. Venetoclax-dexamethasone in t(11;14) myeloma (CANOVA). J Clin Oncol 2026. doi:10.1200/JCO-25-00924
A clot on anticoagulation: is it new, and why?
Is the clot new?
Or the old clot is 4 mm or more thicker under compression.
Not a failure of the drug.
Old clot stays on the ultrasound: 61% of leg veins were still abnormal at 6 months, and 42% at 12 months.313 patients followed with repeated ultrasound (Prandoni 2002). A report that says "clot" a few weeks after the first event is the expected finding.
The first study called 2 mm of growth a recurrence. Two operators measuring the same vein differ by 2 mm on average and by up to 8 mm, so many centers ask for 4 mm, and repeat the scan in a week when it is in between.
Was the drug in the patient?
Then look for a reason in the patient
Cancer
The most common reason for a true failure. After an unexplained clot, 5% have a cancer found within a year.
Antiphospholipid antibodies
Think of them with an arterial event (stroke), a young patient, or clots on a direct oral anticoagulant (apixaban, rivaroxaban, edoxaban, dabigatran).
Heparin-induced thrombocytopenia
Platelets falling 5 to 10 days into heparin, or within hours if heparin was given in the last 100 days. If the bedside score (the 4Ts) is not low: stop all heparin including flushes, start a non-heparin anticoagulant, send the PF4 antibody test.
An unusual site
Liver, portal or splenic veins: JAK2 mutation and PNH (paroxysmal nocturnal hemoglobinuria).
Anatomy
A compressed left iliac vein, or an old vena cava filter left in place.
Three of these change the drug: HIT (no heparin at all), antiphospholipid syndrome (warfarin), cancer (heparin). Two change the plumbing: an unusual site (JAK2, PNH), anatomy (iliac vein, old filter).
Which tests can you trust on anticoagulation?
Antibody and DNA tests are fine on any anticoagulant. Clotting-based tests are not.
A fresh clot by itself also lowers antithrombin, protein C and protein S for a few weeks. A positive antiphospholipid test has to be repeated 12 weeks later. Protein C and S on a direct oral anticoagulant: Connors 2017.
What does not explain it
On warfarin, carriers clotted no more often than non-carriers. A clot on treatment in a carrier still needs the search above.
How often it happens
- Cancer: 6 to 11% on low-molecular-weight heparin and 4 to 8% on a direct oral anticoagulant over 6 to 12 months. The chart is on the next tab.
- Cancer screening after an unexplained clot: adding a CT of the abdomen and pelvis to routine screening found no more cancers (4.5% against 3.2%) and missed about as many.
- Liver and portal vein clots: JAK2 mutation in 41% of hepatic vein and 28% of portal vein thrombosis.
- Vena cava filters at 8 years: fewer lung clots, more leg clots (36% against 28%).
- The 4Ts score for heparin-induced thrombocytopenia (timing, size of the platelet fall, new thrombosis, other causes): when the score was low, 99.8% did not have it.
Sources
Retrieved from PubMed (abstracts and full text), read on Oct 15, 2026.
- Prandoni P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002. doi:10.7326/0003-4819-137-12-200212170-00008
- Prandoni P, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993. doi:10.1161/01.cir.88.4.1730
- Linkins LA, et al. Interobserver agreement on ultrasound measurements of residual vein diameter in patients with previous venous thrombosis. Thromb Res 2006. doi:10.1016/j.thromres.2005.02.011
- Ageno W, et al. Diagnosis of recurrent deep vein thrombosis: ISTH guidance. J Thromb Haemost 2013. doi:10.1111/jth.12301
- Brunton N, et al. Etiology and management of venous thromboembolism recurrence in patients anticoagulated for venous thromboembolism. Res Pract Thromb Haemost 2026. doi:10.1016/j.rpth.2026.106847
- van Es N, et al. Screening for occult cancer in unprovoked venous thromboembolism. Ann Intern Med 2017. doi:10.7326/M17-0868
- Carrier M, et al. Screening for occult cancer in unprovoked venous thromboembolism (SOME). N Engl J Med 2015. doi:10.1056/NEJMoa1506623
- Smalberg JH, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis. Blood 2012. doi:10.1182/blood-2011-09-376517
- Kearon C, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin. Blood 2008. doi:10.1182/blood-2008-06-163279
- Segal JB, et al. Factor V Leiden and prothrombin mutation and recurrent venous thromboembolism. JAMA 2009. doi:10.1001/jama.2009.853
- PREPIC Study Group. Eight-year follow-up of vena cava filters. Circulation 2005. doi:10.1161/CIRCULATIONAHA.104.512834
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001. doi:10.1056/NEJM200104263441704
- Cuker A, et al. Predictive value of the 4Ts score: meta-analysis. Blood 2012. doi:10.1182/blood-2012-07-443051
- Tripodi A, et al. Lupus anticoagulant testing during anticoagulation: ISTH guidance. J Thromb Haemost 2020. doi:10.1111/jth.14846
- Favresse J, et al. Evaluation of the DOAC-Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open 2018. doi:10.1055/s-0038-1657785
- Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017. doi:10.1056/NEJMra1700365
A true failure: what to change
One step up
Before any heparin dose: creatinine clearance and platelets
Clearance under 30 mL/min: enoxaparin 1 mg/kg once daily; do not escalate without anti-Xa levels, ask pharmacy.
Platelets under 50,000: do not escalate; call hematology.
Raising the dose is expert practice, not a trial result. In 212 cancer patients with a clot on treatment, 11% clotted again and 8% bled within 3 months.
Antiphospholipid syndrome changes the drug
INR is the clotting-time ratio used to dose warfarin. After an arterial clot some guidelines use 3 to 4.
Starting or restarting the pill
There is no formal rule on shortening the higher-dose week when the patient has already had several days of heparin. The trials allowed only 36 to 48 hours of it.
In cancer, the choice of drug already matters
Check yourself: clotsThree weeks after a leg clot, on apixaban with no missed doses, a repeat ultrasound reports "thrombus in the same femoral vein". Do you switch to enoxaparin?
Not yet. The same segment, three weeks later, is the expected leftover clot: 61% of veins are still abnormal at 6 months. Compare with the first scan. A segment that was normal before, or 4 mm or more of growth, makes it a new clot. Only then is it a failure, and only then do you move one step up.
The evidence behind the ladder
- Registry of 212 cancer patients with a clot on treatment: moving to low-molecular-weight heparin was linked to about 70% fewer further clots than staying on warfarin. A higher heparin dose did no better than the same dose.
- Within 3 months, 11% clotted again, 8% had a major bleed and 27% died.
- The dose increase of a quarter to a third comes from guidelines and expert practice.
When anticoagulation was stopped for a bleed
- After a major bleed in the first 3 months, anticoagulation was stopped in 69%. Within 30 days, 4.9% had a new clot, 5.9% bled again and 33% died.
- Restarting was linked to about 40% fewer clots and about half the deaths, with almost twice the rebleeding. These data come from adults aged 66 or older, 82% of them anticoagulated for atrial fibrillation. There is no agreed day to restart: it is decided with whoever controlled the bleeding.
Still breathless after a lung clot
- Chronic clot with high lung pressure developed in 3.1% at 1 year and 3.8% at 2 years after a first lung clot.
- If breathlessness persists after 3 months of anticoagulation, repeat the echocardiogram. A ventilation-perfusion scan is the screening test: a normal one rules it out.
The half-dose trials
- General population, after 6 to 12 months of full dose: new clots 1.7% on either apixaban dose against 8.8% on placebo (AMPLIFY-EXT); 1.2% and 1.5% on rivaroxaban against 4.4% on aspirin (EINSTEIN CHOICE).
- Cancer, after 6 months: apixaban 2.5 mg against 5 mg gave 2.1% against 2.8% clots, with less bleeding (12.1% against 15.6%) (API-CAT).
- High-risk patients (RENOVE): 2.2% against 1.8%. Non-inferiority was not shown; bleeding was lower with the half dose.
Sources
Retrieved from PubMed (abstracts and full text) and FDA labels, read on Oct 15, 2026. The dose escalation of a quarter to a third is guideline and expert practice (American College of Chest Physicians; Marx 2026), not a trial result.
- Schulman S, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer. J Thromb Haemost 2015. doi:10.1111/jth.12955
- Carrier M, et al. Dose escalation of low molecular weight heparin for recurrent venous thromboembolism in cancer. J Thromb Haemost 2009. doi:10.1111/j.1538-7836.2009.03326.x
- Stevens SM, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline. Chest 2021. doi:10.1016/j.chest.2021.07.055
- Marx CE, et al. How I treat breakthrough thrombosis in patients with cancer. Blood 2026. doi:10.1182/blood.2025030790
- Mismetti P, et al. Retrievable vena cava filter plus anticoagulation (PREPIC2). JAMA 2015. doi:10.1001/jama.2015.3780
- Lee AYY, et al. Dalteparin versus a coumarin in cancer (CLOT). N Engl J Med 2003. doi:10.1056/NEJMoa025313
- Raskob GE, et al. Edoxaban for cancer-associated venous thromboembolism. N Engl J Med 2018. doi:10.1056/NEJMoa1711948
- Young AM, et al. Rivaroxaban versus dalteparin in cancer (SELECT-D). J Clin Oncol 2018. doi:10.1200/JCO.2018.78.8034
- Agnelli G, et al. Apixaban for venous thromboembolism associated with cancer (Caravaggio). N Engl J Med 2020. doi:10.1056/NEJMoa1915103
- Pengo V, et al. Rivaroxaban vs warfarin in high-risk antiphospholipid syndrome (TRAPS). Blood 2018. doi:10.1182/blood-2018-04-848333
- Woller SC, et al. Apixaban compared with warfarin in thrombotic antiphospholipid syndrome (ASTRO-APS). Blood Adv 2022. doi:10.1182/bloodadvances.2021005808
- Tektonidou MG, et al. EULAR recommendations for antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
- Zuily S, et al. Direct oral anticoagulants in antiphospholipid syndrome: ISTH guidance. J Thromb Haemost 2020. doi:10.1111/jth.14935
- Martin KA, et al. Direct oral anticoagulants in obesity: ISTH update. J Thromb Haemost 2021. doi:10.1111/jth.15358
- Stampfuss J, et al. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013. doi:10.5414/CP201812
- Agnelli G, et al. Apixaban for extended treatment (AMPLIFY-EXT). N Engl J Med 2013. doi:10.1056/NEJMoa1207541
- Weitz JI, et al. Rivaroxaban or aspirin for extended treatment (EINSTEIN CHOICE). N Engl J Med 2017. doi:10.1056/NEJMoa1700518
- Mahé I, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism (API-CAT). N Engl J Med 2025. doi:10.1056/NEJMoa2416112
- Couturaud F, et al. Reduced-dose versus full-dose anticoagulation in high-risk patients (RENOVE). Lancet 2025. doi:10.1016/S0140-6736(24)02842-3
- Little DHW, et al. Rebleeding, thrombosis and mortality with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ 2021. doi:10.1503/cmaj.201433
- Nieto JA, et al. Clinical outcome of patients with major bleeding after venous thromboembolism: findings from the RIETE Registry. Thromb Haemost 2008. doi:10.1160/TH08-06-0390
- Pengo V, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004. doi:10.1056/NEJMoa032274
- FDA labels: apixaban, rivaroxaban and enoxaparin.